Insilico Medicine

TNIK inhibition (anti-fibrotic / senescence) · Idiopathic pulmonary fibrosis

Phase 2Senolytics

Mechanism

TNIK inhibition (anti-fibrotic / senescence)

Intervention class

Small molecule (AI-discovered)

Indication

Idiopathic pulmonary fibrosis

Stage

Phase 2

Evidence

human

Funding

$400M+ raised

Backers

Various

Overview

First fully AI-discovered + AI-designed drug to reach Phase 2 with positive data. TNIK is an aging/fibrosis node. The headline isn't just IPF — it's the validation of an AI discovery engine pointed at age-related disease.

Technology

Insilico Medicine works in Senolytics — Drugs that hunt down and kill the 'zombie' cells that drive aging.

Read the Senolytics brief →

Related companies

Calico

Multiple (cellular senescence, neurodeg.)

Unity Biotechnology

Bcl-xL inhibition (senolytic)

Dorian Therapeutics

USP7 inhibition (senolytic)

Cambrian BioPharma

Multiple (mitophagy, senescence, mTOR)

Company website / source ↗ Open the interactive map →

◢ Boom-cycle briefing

Get ahead of the next biotech boom.

New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.

Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.